{"id":42455,"date":"2025-09-29T16:44:38","date_gmt":"2025-09-29T08:44:38","guid":{"rendered":"https:\/\/flcube.com\/?p=42455"},"modified":"2025-09-29T16:44:38","modified_gmt":"2025-09-29T08:44:38","slug":"hanx-biopharmaceuticals-secures-nmpa-approval-for-hx044%e2%80%91hx008-pd%e2%80%911-therapy-combination-in-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42455","title":{"rendered":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors"},"content":{"rendered":"\n<p><strong>HanX Biopharmaceuticals (Wuhan) Co., Ltd.<\/strong>, a fast\u2011growing Chinese biotech, announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved its <strong>Investigational New Drug (IND)<\/strong> application for a clinical trial of <strong>HX044<\/strong> in combination with the PD\u20111 antibody <strong>HX008 (pucotenlimab)<\/strong>. The approval paves the way for testing the combo in patients with advanced solid tumors across China.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-highlights\">Product Highlights<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>HX044<\/strong> \u2013 a first\u2011in\u2011class bispecific antibody that simultaneously targets <strong>CTLA\u20114<\/strong> and a tumor\u2011associated antigen, designed to overcome PD\u20111 resistance in cancers such as non\u2011small\u2011cell lung cancer, melanoma, renal cell carcinoma, and gastrointestinal malignancies.<\/li>\n\n\n\n<li><strong>HX008 (pucotenlimab)<\/strong> \u2013 a humanized monoclonal antibody with high FcRn affinity, conferring an extended half\u2011life and improved patient compliance. Developed jointly with <strong>Lepu Medical<\/strong>, it remains a leading PD\u20111 therapeutic in the Chinese market.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-strategic-implications\">Clinical &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Expanded Therapeutic Window<\/strong> \u2013 HX044\u2019s dual\u2011target design enhances anti\u2011tumor immune responses while mitigating the safety concerns that have limited earlier CTLA\u20114 agents.<\/li>\n\n\n\n<li><strong>Patient\u2011Centric Design<\/strong> \u2013 HX008\u2019s long half\u2011life reduces dosing frequency, potentially improving adherence and quality of life for oncology patients.<\/li>\n\n\n\n<li><strong>Regulatory Milestone<\/strong> \u2013 NMPA clearance is a critical step for HanX to launch a global clinical program, positioning the company as a key player in next\u2011generation checkpoint inhibitors.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-outlook\">Market Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Advantage<\/strong> \u2013 The HX044\u2011HX008 combination targets the growing segment of PD\u20111\u2011resistant tumors, offering a differentiated therapeutic option against established PD\u20111\/PD\u2011L1 agents.<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong> \u2013 Successful clinical outcomes could unlock multi\u2011billion\u2011dollar opportunities in China and beyond, aligning with HanX\u2019s aggressive pipeline strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":42456,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,29,2333,18],"class_list":["post-42455","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-combination-therapy","tag-hanx-biopharmaceuticals","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a clinical trial of HX044 in combination with the PD\u20111 antibody HX008 (pucotenlimab). The approval paves the way for testing the combo in patients with advanced solid tumors across China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42455\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a clinical trial of HX044 in combination with the PD\u20111 antibody HX008 (pucotenlimab). The approval paves the way for testing the combo in patients with advanced solid tumors across China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42455\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T08:44:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors\",\"datePublished\":\"2025-09-29T08:44:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2901.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"Combination therapy\",\"Hanx Biopharmaceuticals\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42455#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42455\",\"name\":\"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2901.webp\",\"datePublished\":\"2025-09-29T08:44:38+00:00\",\"description\":\"HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a clinical trial of HX044 in combination with the PD\u20111 antibody HX008 (pucotenlimab). The approval paves the way for testing the combo in patients with advanced solid tumors across China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42455\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42455#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a clinical trial of HX044 in combination with the PD\u20111 antibody HX008 (pucotenlimab). The approval paves the way for testing the combo in patients with advanced solid tumors across China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42455","og_locale":"en_US","og_type":"article","og_title":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors","og_description":"HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a clinical trial of HX044 in combination with the PD\u20111 antibody HX008 (pucotenlimab). The approval paves the way for testing the combo in patients with advanced solid tumors across China.","og_url":"https:\/\/flcube.com\/?p=42455","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-29T08:44:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42455#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42455"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors","datePublished":"2025-09-29T08:44:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42455"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42455#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp","keywords":["Cancer","Clinical trial approval \/ initiation","Combination therapy","Hanx Biopharmaceuticals","PD-1\/L1"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42455#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42455","url":"https:\/\/flcube.com\/?p=42455","name":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42455#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42455#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp","datePublished":"2025-09-29T08:44:38+00:00","description":"HanX Biopharmaceuticals (Wuhan) Co., Ltd., a fast\u2011growing Chinese biotech, announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for a clinical trial of HX044 in combination with the PD\u20111 antibody HX008 (pucotenlimab). The approval paves the way for testing the combo in patients with advanced solid tumors across China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42455#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42455"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42455#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp","width":1080,"height":608,"caption":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42455#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HanX Biopharmaceuticals Secures NMPA Approval for HX044\u2011HX008 PD\u20111 Therapy Combination in Advanced Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42455"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42455\/revisions"}],"predecessor-version":[{"id":42457,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42455\/revisions\/42457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42456"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}